Paper39211339
Therapy of IgA nephropathy: time for a paradigm change.
Barratt J and 2 others. Front Med (Lausanne), 2024. Cited by 41 papers, by iCite.
Cite this record
ConductScience Library. Therapy of IgA nephropathy: time for a paradigm change. Papers, record 39211339. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39211339
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34247883 | IgA Nephropathy: Core Curriculum 2021. | Am J Kidney Dis | 2021 | https://conductscience.org/library/papers/34247883 | PubMed |
| 2 | 29988921 | Bortezomib for Reduction of Proteinuria in IgA Nephropathy. | Kidney Int Rep | 2018 | https://conductscience.org/library/papers/29988921 | PubMed |
| 3 | 35967104 | Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria. | Kidney Int Rep | 2022 | https://conductscience.org/library/papers/35967104 | PubMed |
| 4 | 15673288 | Pathways to nephron loss starting from glomerular diseases-insights from animal models. | Kidney Int | 2005 | https://conductscience.org/library/papers/15673288 | PubMed |
| 5 | 23715783 | Remnant nephron physiology and the progression of chronic kidney disease. | Pediatr Nephrol | 2014 | https://conductscience.org/library/papers/23715783 | PubMed |
| 6 | 23782179 | IgA nephropathy. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23782179 | PubMed |
| 7 | 34640530 | Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment. | J Clin Med | 2021 | https://conductscience.org/library/papers/34640530 | PubMed |
| 8 | 32269271 | The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: A network meta-analysis. | Sci Rep | 2020 | https://conductscience.org/library/papers/32269271 | PubMed |
| 9 | 22318424 | An update on the pathogenesis and treatment of IgA nephropathy. | Kidney Int | 2012 | https://conductscience.org/library/papers/22318424 | PubMed |
| 10 | 37591292 | Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. | Lancet | 2023 | https://conductscience.org/library/papers/37591292 | PubMed |
| 11 | 37914086 | Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. | Kidney Int | 2024 | https://conductscience.org/library/papers/37914086 | PubMed |
| 12 | 36927642 | EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. | Ann Rheum Dis | 2024 | https://conductscience.org/library/papers/36927642 | PubMed |
| 13 | 36685528 | Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review. | Front Immunol | 2022 | https://conductscience.org/library/papers/36685528 | PubMed |
| 14 | 34211943 | Acute Kidney Injury in Pediatric Diabetic Kidney Disease. | Front Pediatr | 2021 | https://conductscience.org/library/papers/34211943 | PubMed |
| 15 | 34495361 | Current treatment of IgA nephropathy. | Semin Immunopathol | 2021 | https://conductscience.org/library/papers/34495361 | PubMed |
| 16 | 36351458 | Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. | Lancet | 2022 | https://conductscience.org/library/papers/36351458 | PubMed |
| 17 | 32450154 | After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. | Kidney Int | 2020 | https://conductscience.org/library/papers/32450154 | PubMed |
| 18 | 37705898 | Clinicopathological Characteristics of Adult IgA Nephropathy in the United States. | Kidney Int Rep | 2023 | https://conductscience.org/library/papers/37705898 | PubMed |
| 19 | 12488422 | Remission of renal disease: recounting the challenge, acquiring the goal. | J Clin Invest | 2002 | https://conductscience.org/library/papers/12488422 | PubMed |
| 20 | 33653703 | Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. | Open Heart | 2021 | https://conductscience.org/library/papers/33653703 | PubMed |
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42884063 | From Susceptibility Loci to Therapeutic Targets: The Genetic Architecture of IgA Nephropathy. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42884063 | PubMed |
| 42787250 | Comparison of efficacy and safety of systemic glucocorticoids and Nefecon in IgA nephropathy patients: a real-world retrospective cohort study. | Front Immunol | 2026 | https://conductscience.org/library/papers/42787250 | PubMed |
| 42756351 | Tonsillar Tfh cells contribute to the pathogenesis of IgA nephropathy in collaboration with memory B cells. | Front Immunol | 2026 | https://conductscience.org/library/papers/42756351 | PubMed |
| 42746507 | Twelve-month real-world outcomes of sparsentan in a multicenter Spanish IgA nephropathy cohort. | Clin Kidney J | 2026 | https://conductscience.org/library/papers/42746507 | PubMed |
| 42682870 | Real-world multicenter evidence on Nefecon for attenuating proteinuria and kidney function decline in IgA nephropathy. | Front Immunol | 2026 | https://conductscience.org/library/papers/42682870 | PubMed |
| 42668642 | Toward a Treatment Goal Framework for Emerging Therapies in IgAN: Implications for Future Research. | Kidney Int Rep | 2026 | https://conductscience.org/library/papers/42668642 | PubMed |
| 42633049 | Efficacy and safety of sibeprenlimab in IgA nephropathy: interim analysis of the China cohort in the phase 3 VISIONARY trial. | Clin Kidney J | 2026 | https://conductscience.org/library/papers/42633049 | PubMed |
| 42587782 | Plasma Proteomics in IgA Nephropathy: From Circulating Biomarkers to Molecular Endotypes. | Cells | 2026 | https://conductscience.org/library/papers/42587782 | PubMed |
| 42422566 | Long-term real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors. | Clin Kidney J | 2026 | https://conductscience.org/library/papers/42422566 | PubMed |
| 42278897 | Segmental Glomerulosclerosis Subclassification in the Oxford Classification System (MEST-C) Improves the International IgA Nephropathy Prediction Tool. | J Clin Med | 2026 | https://conductscience.org/library/papers/42278897 | PubMed |
| 42146603 | Inhibition of p65 NF-κB enhances production of galactose-deficient IgA1 through suppression of C1GALT1 and SP1 in plasmablast-like cell subpopulations. | bioRxiv | 2026 | https://conductscience.org/library/papers/42146603 | PubMed |
| 42121963 | IgA Nephropathy: Mechanisms, Risk Stratification, and Precision Therapy. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42121963 | PubMed |
| 41904427 | Efficacy and safety of sibeprenlimab in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials. | BMC Nephrol | 2026 | https://conductscience.org/library/papers/41904427 | PubMed |
| 41788457 | Immunoglobulin A Nephropathy With Associated Thrombotic Microangiopathy: Biopsy and Clinical Case Series. | Clin Med Insights Case Rep | 2026 | https://conductscience.org/library/papers/41788457 | PubMed |
| 41573494 | Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine. | Cureus | 2025 | https://conductscience.org/library/papers/41573494 | PubMed |
| 41479816 | Prognostic value of the MEST-C score in long-term outcomes of immunoglobulin A nephropathy patients: Insights from a developing country. | World J Nephrol | 2025 | https://conductscience.org/library/papers/41479816 | PubMed |
| 41426049 | Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in Management. | Kidney Int Rep | 2025 | https://conductscience.org/library/papers/41426049 | PubMed |
| 41402784 | Efficacy and safety of BAFF/APRIL dual antagonists in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials. | BMC Nephrol | 2025 | https://conductscience.org/library/papers/41402784 | PubMed |
| 41393859 | Targeting B cells in IgA nephropathy: from pathogenic insight to therapeutic horizon. | Clin Kidney J | 2025 | https://conductscience.org/library/papers/41393859 | PubMed |
| 41358049 | Case Report: Maximizing the anti-proteinuric response: a multicenter real-world sparsentan case series in IgA disorders. | Front Nephrol | 2025 | https://conductscience.org/library/papers/41358049 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AGTR1 | 185 | PubTator's text mining | https://conductscience.org/library/genes/185 | NCBI Gene |
| TNFSF13B | 10673 | PubTator's text mining | https://conductscience.org/library/genes/10673 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39211339
GET https://conductscience.org/api/papers/v1/39211339/references?page=2